The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Amy Schumer’s experience with Mounjaro has been vastly different from when she tried an alternative weight-loss medication ...

Semaglutide is already available in Ireland through diabetes medication Ozempic. However, its producer Novo Nordisk uses the ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

The software company SAP has replaced the Danish pharmaceutical giant Novo Nordisk as the most valuable company in Europe.

Gabby Thomas is sharing the hilariously relatable reason she’s not a fan of Ozempic. On March 21, the 28-year-old track star, ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.